Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?

CLINICAL CANCER RESEARCH（2024）

引用 0|浏览4

暂无评分

摘要

Acquired mutations in BTK, PLCG2, and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective retreatment strategies.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要